Myocardial Ischemia – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 5 PAGES: 64

More Info
									Myocardial Ischemia – Pipeline Review, H1 2012




           Myocardial Ischemia – Pipeline Review, H1 2012
                                                                                          Reference Code: GMDHC1696IDB
                                                                                            Publication Date: January 2012




Myocardial Ischemia – Pipeline Review, H1 2012                                             GMDHC1696IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Myocardial Ischemia – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 5
    List of Figures ................................................................................................................................................................................ 6
Introduction......................................................................................................................................................................................... 7
    Global Markets Direct Report Coverage ........................................................................................................................................ 7
Myocardial Ischemia Overview ........................................................................................................................................................... 8
Therapeutics Development................................................................................................................................................................. 9
    An Overview of Pipeline Products for Myocardial Ischemia........................................................................................................... 9
Myocardial Ischemia Therapeutics under Development by Companies ........................................................................................... 11
Myocardial Ischemia Therapeutics under Investigation by Universities/Institutes ............................................................................ 13
Late Stage Products ......................................................................................................................................................................... 14
    Comparative Analysis .................................................................................................................................................................. 14
Mid Clinical Stage Products.............................................................................................................................................................. 15
    Comparative Analysis .................................................................................................................................................................. 15
Early Clinical Stage Products ........................................................................................................................................................... 16
    Comparative Analysis .................................................................................................................................................................. 16
Pre-Clinical Stage Products.............................................................................................................................................................. 17
    Comparative Analysis .................................................................................................................................................................. 17
Myocardial Ischemia Therapeutics – Products under Development by Companies ......................................................................... 18
Myocardial Ischemia Therapeutics – Products under Investigation by Universities/Institutes .......................................................... 19
Companies Involved in Myocardial Ischemia Therapeutics Development ........................................................................................ 20
    Cardium Therapeutics, Inc........................................................................................................................................................... 20
    Cook Medical Incorporated .......................................................................................................................................................... 21
    Advanced Cell Technology, Inc. .................................................................................................................................................. 22
    Cytori Therapeutics, Inc............................................................................................................................................................... 23
    CardioVascular BioTherapeutics, Inc. ......................................................................................................................................... 24
    Unigene Laboratories, Inc. .......................................................................................................................................................... 25
    Viromed Co., Ltd.......................................................................................................................................................................... 26
    Baxter Healthcare Corporation .................................................................................................................................................... 27
    Eribis Pharmaceuticals AB .......................................................................................................................................................... 28
    Biopeutics co., Ltd. ...................................................................................................................................................................... 29
Myocardial Ischemia – Therapeutics Assessment............................................................................................................................ 30
    Assessment by Monotherapy Products ....................................................................................................................................... 30
    Assessment by Combination Products ........................................................................................................................................ 31
    Assessment by Route of Administration ...................................................................................................................................... 32
    Assessment by Molecule Type .................................................................................................................................................... 34
Drug Profiles..................................................................................................................................................................................... 36
    Generx - Drug Profile................................................................................................................................................................... 36
         Product Description................................................................................................................................................................. 36
         Mechanism of Action ............................................................................................................................................................... 36
         R&D Progress ......................................................................................................................................................................... 36
    Annexin Analogs - Drug Profile.................................................................................................................................................... 37



Myocardial Ischemia – Pipeline Review, H1 2012                                                                                                GMDHC1696IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Myocardial Ischemia – Pipeline Review, H1 2012




        Product Description................................................................................................................................................................. 37
        Mechanism of Action ............................................................................................................................................................... 37
        R&D Progress ......................................................................................................................................................................... 37
    VM202 - Drug Profile ................................................................................................................................................................... 38
        Product Description................................................................................................................................................................. 38
        Mechanism of Action ............................................................................................................................................................... 38
        R&D Progress ......................................................................................................................................................................... 38
    Papeilin - Drug Profile.................................................................................................................................................................. 40
        Product Description................................................................................................................................................................. 40
        Mechanism of Action ............................................................................................................................................................... 40
        R&D Progress ......................................................................................................................................................................... 40
    Eprex - Drug Profile ..................................................................................................................................................................... 41
        Product Description................................................................................................................................................................. 41
        Mechanism of Action ............................................................................................................................................................... 41
        R&D Progress ......................................................................................................................................................................... 41
    FGF-1141 - Drug Profile .............................................................................................................................................................. 42
        Product Description................................................................................................................................................................. 42
        Mechanism of Action ............................................................................................................................................................... 42
        R&D Progress ......................................................................................................................................................................... 42
    Evasin-3 - Drug Profile ................................................................................................................................................................ 43
        Product Description................................................................................................................................................................. 43
        Mechanism of Action ............................................................................................................................................................... 43
        R&D Progress ......................................................................................................................................................................... 43
    Adenosine - Drug Profile ..................................................
								
To top